MicroRNA‑208a‑3p contributes to connexin40 remolding in human chronic atrial fibrillation

Li,Shanshan; Jiang,Zhiyuan; Wen,Lina; Feng,Guirong; Zhong,Guoqiang

doi:10.3892/etm.2017.5225

MicroRNA‑208a‑3p contributes to connexin40 remolding in human chronic atrial fibrillation

Authors:
- Shanshan Li
- Zhiyuan Jiang
- Lina Wen
- Guirong Feng
- Guoqiang Zhong
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/etm.2017.5225
Pages: 5355-5362
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that connexin40 (Cx40) remolding is involved in atrial fibrillation (AF). GJA5 encoding Cx40 is a potential target mRNA of microRNA‑208a‑3p (miR‑208a‑3p), as indicated by preliminary bioinformatics analyses. However, the exact effect of miR‑208a‑3p on Cx40 in human chronic AF has remained elusive. The present study demonstrated the role of miR‑208a‑3p in human chronic AF and further investigated the effect of miR‑208a‑3p on Cx40 expression. A total of 19 patients with AF and 18 patients with sinus rhythm (SR) were enrolled. The AC16 cell line was treated with miR‑208a‑3p inhibitor or mimics. The miR‑208a‑3p in right atrial appendage (RAA) tissues of patients was measured by in situ hybridization and reverse‑transcription quantitative polymerase chain reaction (RT‑qPCR). Furthermore, the expression of Cx40 in the RAA of patients and in AC16 cells treated with miR‑208a‑3p inhibitor or mimics were detected by RT‑qPCR and western blot analysis. A luciferase assay was performed to confirm whether Cx40 was directly targeted by miR‑208a‑3p. The miR‑208a‑3p levels in patients with AF were significantly increased compared with those in patients with SR. Conversely, the Cx40 protein levels were significantly decreased and lateralization of Cx40 was observed in patients with AF. miR‑208a‑3p inhibitor led to a significant upregulation of the protein expression of Cx40 in AC16 cells, while miR‑208a‑3p mimics led to a significant downregulation. However, the luciferase assay demonstrated that GJA5 was not a direct target gene of miR‑208a‑3p. The findings still suggested that miR‑208a‑3p may be involved in human chronic AF by mediating atrial Cx40 remolding, and may represent a potential therapeutic target for AF.

View Figures

View References

1	Rahman F, Kwan GF and Benjamin EJ: Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 11:639–654. 2014. View Article : Google Scholar : PubMed/NCBI
2	Nattel S and Dobrev D: Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. Nat Rev Cardiol. 13:575–590. 2016. View Article : Google Scholar : PubMed/NCBI
3	Wakili R, Voigt N, Kääb S, Dobrev D and Nattel S: Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 121:2955–2968. 2011. View Article : Google Scholar : PubMed/NCBI
4	Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA and Bauer A: Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res. 92:218–225. 2011. View Article : Google Scholar : PubMed/NCBI
5	Segretain D and Falk MM: Regulation of connexin biosynthesis, assembly, gap junction formation, and removal. Biochim Biophys Acta. 1662:3–21. 2004. View Article : Google Scholar : PubMed/NCBI
6	Davis LM, Kanter HL, Beyer EC and Saffitz JE: Distinct gap junction protein phenotypes in cardiac tissues with disparate conduction properties. J Am Coll Cardiol. 24:1124–1132. 1994. View Article : Google Scholar : PubMed/NCBI
7	Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS and Donahue JK: Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 125:216–225. 2012. View Article : Google Scholar : PubMed/NCBI
8	van Rooij E and Olson EN: MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles. Nat Rev Drug Discov. 11:860–872. 2012. View Article : Google Scholar : PubMed/NCBI
9	Luo X, Yang B and Nattel S: MicroRNAs and atrial fibrillation: Mechanisms and translational potential. Nat Rev Cardiol. 12:80–90. 2015. View Article : Google Scholar : PubMed/NCBI
10	Nattel S and Harada M: Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives. J Am Coll Cardiol. 63:2335–2345. 2014. View Article : Google Scholar : PubMed/NCBI
11	Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Saito S, Ueno T, Kuratani T and Sawa Y: Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery. PLoS One. 8:e733972013. View Article : Google Scholar : PubMed/NCBI
12	Radtke A, Hanke T, Yan J, Godau B, Cordes J, Nigam V, Sievers HH and Mohamed SA: MicroRNA 208 in atrial fibrillation. J Clin Exp Cardiol. 5:3252014.
13	January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 64:e1–e76. 2014. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:2015. View Article : Google Scholar
16	Betel D, Koppal A, Agius P, Sander C and Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11:R902010. View Article : Google Scholar : PubMed/NCBI
17	Rehmsmeier M, Steffen P, Hochsmann M and Giegerich R: Fast and effective prediction of microRNA/target duplexes. RNA. 10:1507–1517. 2004. View Article : Google Scholar : PubMed/NCBI
18	Davidson MM, Nesti C, Palenzuela L, Walker WF, Hernandez E, Protas L, Hirano M and Isaac ND: Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell Cardiol. 39:133–147. 2005. View Article : Google Scholar : PubMed/NCBI
19	Firouzi M, Ramanna H, Kok B, Jongsma HJ, Koeleman BP, Doevendans PA, Groenewegen WA and Hauer RN: Association of human connexin40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation. Circ Res. 95:e29–e33. 2004. View Article : Google Scholar : PubMed/NCBI
20	Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, et al: Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med. 354:2677–2688. 2006. View Article : Google Scholar : PubMed/NCBI
21	Juang JM, Chern YR, Tsai CT, Chiang FT, Lin JL, Hwang JJ, Hsu KL, Tseng CD, Tseng YZ and Lai LP: The association of human connexin 40 genetic polymorphisms with atrial fibrillation. Int J Cardiol. 116:107–112. 2007. View Article : Google Scholar : PubMed/NCBI
22	Kostin S, Klein G, Szalay Z, Hein S, Bauer EP and Schaper J: Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 54:361–379. 2002. View Article : Google Scholar : PubMed/NCBI
23	Rucker-Martin C, Milliez P, Tan S, Decrouy X, Recouvreur M, Vranckx R, Delcayre C, Renaud JF, Dunia I, Segretain D and Hatem SN: Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res. 72:69–79. 2006. View Article : Google Scholar : PubMed/NCBI
24	Xiao P, Gao C, Fan J, Du H, Long Y and Yin Y: Blockade of angiotensin II improves hyperthyroid induced abnormal atrial electrophysiological properties. Regul Pept. 169:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hagendorff A, Schumacher B, Kirchhoff S, Lüderitz B and Willecke K: Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. Circulation. 99:1508–1515. 1999. View Article : Google Scholar : PubMed/NCBI
26	Oliveira-Carvalho V, Carvalho VO and Bocchi EA: The emerging role of miR-208a in the heart. DNA Cell Biol. 32:8–12. 2013. View Article : Google Scholar : PubMed/NCBI
27	van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J and Olson EN: Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 316:575–579. 2007. View Article : Google Scholar : PubMed/NCBI
28	Satoh M, Minami Y, Takahashi Y, Tabuchi T and Nakamura M: Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail. 16:404–410. 2010. View Article : Google Scholar : PubMed/NCBI
29	Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy A, Provencher S, Bonnet S and Michelakis ED: A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension. Circ Res. 116:56–69. 2015. View Article : Google Scholar : PubMed/NCBI
30	Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, et al: MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 119:2772–2786. 2009. View Article : Google Scholar : PubMed/NCBI
31	Linhares VL, Almeida NA, Menezes DC, Elliott DA, Lai D, Beyer EC, de Carvalho Campos AC and Costa MW: Transcriptional regulation of the murine Connexin40 promoter by cardiac factors Nkx2-5, GATA4 and Tbx5. Cardiovasc Res. 64:402–411. 2004. View Article : Google Scholar : PubMed/NCBI